Janus | Jotup

EQS-News: neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector

Retrieved on:

Venerdì, Maggio 10, 2024

Janus, Investment, Dubai Healthcare City, Health, Cleveland Clinic, AG, Growth, Senior, GCC, Mental health, Cleveland Clinic Abu Dhabi, Management

neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector

Key Points:

neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector
The issuer is solely responsible for the content of this announcement.
neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector
Tariq previously held leadership roles at Dubai Healthcare City, Mubadala Healthcare's Cleveland Clinic Abu Dhabi, and Proximie
Dubai, UAE and Munich, Germany, 7.
May 2024 - neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice, today announced the appointment of Tariq El-Titi as Senior Vice President for the Middle East and North-Africa (MENA) region.
Focused on bringing disruptive new health technologies to the Middle East, Tariq founded Janus Ventures in 2018, underscoring his commitment to driving innovation in the healthcare sector.

EQS-News: Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on:

Venerdì, Maggio 10, 2024

January 2024: Announced a three-tranche private placement totaling up to $240 million, with participation from select new and existing investors.

Key Points:

January 2024: Announced a three-tranche private placement totaling up to $240 million, with participation from select new and existing investors.
With these funds, Immunic expects to be able to fund its operations into the third quarter of 2025.
Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
An archived replay of the webcast will be available approximately one hour after completion on Immunic’s website at: ir.imux.com/events-and-presentations .

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Retrieved on:

Giovedì, Maggio 9, 2024

NEW YORK and WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the first quarter ending March 31, 2024, and provided an update on recent business achievements.

Key Points:

“The first quarter of 2024 was highlighted by the initiation of our Phase 2 MaGic trial of DNTH103 for patients with gMG.
Initial top-line results from this trial are anticipated to be available in the second half of 2025.
Dianthus successfully completed a private investment in public equity (“PIPE”) financing in January 2024 that resulted in gross proceeds of approximately $230 million.
Additional Information - For additional information on the Company’s financial results for the quarter ended March 31, 2024, please refer to the Form 10-Q filed with the SEC.

Janus International Group Reports First Quarter 2024 Financial Results

Retrieved on:

Giovedì, Maggio 9, 2024

Manufacturing, Other Manufacturing, Other Construction & Property, Commercial Building & Real Estate, Construction & Property, Janus, Commercial, Regulation S-K, Self, JBI, Tax, Regulation, International Marxist Group, Share repurchase, Growth, Management

Janus International Group, Inc. (NYSE: JBI) (“Janus” or the “Company”), a leading provider of building product solutions and cutting-edge access control technologies for the self-storage and other commercial and industrial sectors, today announced financial results for the first quarter ended March 30, 2024.

Key Points:

Janus International Group, Inc. (NYSE: JBI) (“Janus” or the “Company”), a leading provider of building product solutions and cutting-edge access control technologies for the self-storage and other commercial and industrial sectors, today announced financial results for the first quarter ended March 30, 2024.
Net income of $30.7 million, or $0.21 per diluted share, a 18.1% increase compared to $26.0 million, or $0.18 per diluted share in the first quarter of 2023.
Adjusted Net Income per diluted share of $0.21, a 16.7% increase compared to $0.18 per diluted share in the first quarter of 2023.
“Driven by strength in our Self-Storage segment we delivered first quarter results in-line with our expectations, and we believe we are set up well for a successful 2024,” said Ramey Jackson, Chief Executive Officer.

Protective Life Corporation Announces Board of Directors Updates

Retrieved on:

Martedì, Maggio 7, 2024

Other Professional Services, Professional Services, Insurance, Dai, Janus, EVP, Dai-ichi, Digital, Senior, Janus Capital Group, OJW, Knowledge, Management

Protective Life Corporation (Protective), a subsidiary of Dai-ichi Life Holdings, Inc. (Dai-ichi, TSE:8750), announces updates to its board of directors.

Key Points:

Protective Life Corporation (Protective), a subsidiary of Dai-ichi Life Holdings, Inc. (Dai-ichi, TSE:8750), announces updates to its board of directors.
“Through their diverse and robust experience, Protective’s Board of Directors have collectively helped guide the company to our current position of strength,” said Michael J. Morrissey, Chairman of Protective’s Board of Directors.
Hitoshi Yamaguchi, Representative Director and Senior Managing Executive Officer of Dai-ichi, Takashi Iida, Director and Managing Executive Officer of The Dai-ichi Life Insurance Co., Ltd., and Koichi Nishiyama, Managing Executive Officer of The Dai-ichi Life Insurance Co,.
For more information about Protective’s Board of Directors, visit https://investor.protective.com/board-of-directors .

TENEO EXPANDS MIDWEST OPERATIONS

Retrieved on:

Martedì, Maggio 7, 2024

Janus, Service provider, Management consulting, Risk, Commerce, Communication, Janus Capital Group, Campaign finance, Ariel Investments, Government, Senior advisor, Investment

NEW YORK, May 7, 2024 /PRNewswire/ -- Teneo, the global CEO advisory firm, today announced that Peter Thompson has joined the firm and will be based in Chicago. He will operate across Teneo's five business segments: Strategy & Communications, Financial Advisory, Management Consulting, Risk Advisory and People Advisory.

Key Points:

Thompson joins Teneo from Lazard Frères & Co., where he was most recently Chairman of Midwest Advisory.
Thompson's appointment as a Senior Advisor is part of a broader expansion of Teneo's operations in Chicago and across the Midwest.
"Chicago and the Midwest region are home to dozens of Teneo clients, and today's announcement demonstrates our commitment to growing our team in this critical market," said Paul Keary, CEO of Teneo.
"I am thrilled to be joining Teneo and helping to grow the firm's presence across the Midwest," said Peter Thompson.

Janus Health Appoints New Chief Product Officer

Retrieved on:

Martedì, Maggio 7, 2024

Janus, CPO, Automation, RCM

CHICAGO, May 7, 2024 /PRNewswire/ -- Janus Health, an innovative resource in revenue cycle management technology, announced the addition of John Garcia as chief product officer. With more than two decades of experience as a product management leader, Garcia will lead product development at Janus Health, including the strategy, vision and design of new features and solutions to further meet the needs of customers.

Key Points:

CHICAGO, May 7, 2024 /PRNewswire/ -- Janus Health, an innovative resource in revenue cycle management technology, announced the addition of John Garcia as chief product officer.
With more than two decades of experience as a product management leader, Garcia will lead product development at Janus Health, including the strategy, vision and design of new features and solutions to further meet the needs of customers.
His extensive experience leading product management teams to develop market-leading RCM technology based on customer needs is impressive," said Janus Health founder, Brendan Downing.
Prior to joining Janus Health, Garcia served as CPO of Revecore, a revenue integrity and complex claims solution provider.

neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector

Retrieved on:

Martedì, Maggio 7, 2024

Janus, Investment, Dubai Healthcare City, Health, Cleveland Clinic, AG, Growth, Senior, GCC, Mental health, Cleveland Clinic Abu Dhabi, Management

DUBAI, UAE, May 7, 2024 /PRNewswire/ -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice, today announced the appointment of Tariq El-Titi as Senior Vice President for the Middle East and North-Africa (MENA) region.

Key Points:

Tariq is a seasoned healthcare specialist, bringing with him a wealth of experience in healthcare start-up ventures and strategic C-level leadership roles.
Throughout his career, Tariq has worked in various private and publicly listed multinationals, semi-government organizations, and start-up companies across the UK, Europe, and the Middle East.
Focused on bringing disruptive new health technologies to the Middle East, Tariq founded Janus Ventures in 2018, underscoring his commitment to driving innovation in the healthcare sector.
"We warmly welcome Tariq to the neurocare team," said Thomas Mechtersheimer, CEO of neurocare Group AG.

neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector

Retrieved on:

Martedì, Maggio 7, 2024

Janus, Investment, Dubai Healthcare City, Health, Cleveland Clinic, AG, Growth, Senior, GCC, Mental health, Cleveland Clinic Abu Dhabi, Management

DUBAI, UAE, May 7, 2024 /PRNewswire/ -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice, today announced the appointment of Tariq El-Titi as Senior Vice President for the Middle East and North-Africa (MENA) region.

Key Points:

Tariq is a seasoned healthcare specialist, bringing with him a wealth of experience in healthcare start-up ventures and strategic C-level leadership roles.
Throughout his career, Tariq has worked in various private and publicly listed multinationals, semi-government organizations, and start-up companies across the UK, Europe, and the Middle East.
Focused on bringing disruptive new health technologies to the Middle East, Tariq founded Janus Ventures in 2018, underscoring his commitment to driving innovation in the healthcare sector.
"We warmly welcome Tariq to the neurocare team," said Thomas Mechtersheimer, CEO of neurocare Group AG.

Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Retrieved on:

Venerdì, Maggio 3, 2024

Janus, Sale, Prospectus, Montgomery Street, Suite, Security (finance), Form, BLA, S-3, Attention, Telephone

The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the pre-funded warrants are exercised in full.

Key Points:

The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the pre-funded warrants are exercised in full.
The closing of the offering is expected to occur on or about May 7, 2024, subject to the satisfaction of customary closing conditions.
The offering included participation from both new and existing investors, including Adage Capital Partners, L.P., Janus Henderson Investors, Nantahala Capital, Suvretta Capital, Vivo Capital, and other healthcare-dedicated investors.
The gross proceeds to Abeona from this offering are expected to be approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses.